Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

A charity boss who once tipped the scales at more than 28st says weight-loss injections have changed the way he thinks about ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Goldberg said the company "melded" a CBS News Sunday Mornings appearance from her to sell “bad weight loss drugs." ...

Whoopi Goldberg issued a stern warning to her fans, "Do not look at this!" after a problem was brought to her attention.